Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of BI 1265162 in Healthy Volunteers
NCT03907280Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 1265162 in cystic fibrosis (CF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area Under the Concentration-time Curve of BI 1265162 in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Dose-normalized at 24 hours. Started Apr 2019; status: completed.
02
Drugs
BI 1265162
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03907280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907280.